TG Therapeutics Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TG Therapeutics stock.
View analyst ratings for TG Therapeutics or view top-rated stocks.

Wall Street analysts have given TG Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TG Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

TG Therapeutics saw a increase in short interest during the month of August. As of August 13th, there was short interest totaling 12,820,000 shares, an increase of 12.2% from the July 29th total of 11,430,000 shares. Based on an average trading volume of 1,400,000 shares, the days-to-cover ratio is currently 9.2 days. Approximately 9.7% of the shares of the stock are sold short.
View TG Therapeutics' Short Interest.

TG Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for TG Therapeutics.

TG Therapeutics, Inc. (NASDAQ:TGTX) announced its quarterly earnings data on Sunday, August, 1st. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.11. TG Therapeutics had a negative trailing twelve-month return on equity of 90.75% and a negative net margin of 14,271.13%.
View TG Therapeutics' earnings history.

TG Therapeutics' stock was trading at $10.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TGTX shares have increased by 206.0% and is now trading at $30.63.
View which stocks have been most impacted by COVID-19.

4 equities research analysts have issued 1-year price objectives for TG Therapeutics' stock. Their forecasts range from $48.00 to $95.00. On average, they expect TG Therapeutics' share price to reach $69.25 in the next twelve months. This suggests a possible upside of 126.1% from the stock's current price.
View analysts' price targets for TG Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to TG Therapeutics include Viatris (VTRS), Elanco Animal Health (ELAN), BioMarin Pharmaceutical (BMRN), Maravai LifeSciences (MRVI), Zai Lab (ZLAB), Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), CureVac (CVAC), Bausch Health Companies (BHC), Grifols (GRFS), Teva Pharmaceutical Industries (TEVA), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), Biohaven Pharmaceutical (BHVN) and Mirati Therapeutics (MRTX).
View all of TGTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Cara Therapeutics (CARA), Gilead Sciences (GILD), UrtheCast (UR), Verastem (VSTM), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE) and Corbus Pharmaceuticals (CRBP).

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

TG Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (13.20%), Vanguard Group Inc. (8.29%), BlackRock Inc. (5.90%), State Street Corp (2.55%), RA Capital Management L.P. (2.36%) and Lord Abbett & CO. LLC (2.00%). Company insiders that own TG Therapeutics stock include Ra Capital Management, LP, William James Kennedy and Yann Echelard.
View institutional ownership trends for TG Therapeutics.

TGTX stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, RA Capital Management L.P., BlackRock Inc., Woodline Partners LP, Goldman Sachs Group Inc., Bank of America Corp DE, Credit Suisse AG, and Emerald Advisers LLC.
View insider buying and selling activity for TG Therapeutics or view top insider-selling stocks.

TGTX stock was purchased by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, FMR LLC, Vanguard Group Inc., Fisher Asset Management LLC, JPMorgan Chase & Co., State Street Corp, Price T Rowe Associates Inc. MD, and Morgan Stanley.
View insider buying and selling activity for TG Therapeutics or or view top insider-buying stocks.

Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TGTX stock can currently be purchased for approximately $30.63.

TG Therapeutics has a market capitalization of $4.33 billion and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-279,380,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis.

TG Therapeutics employs 272 workers across the globe.

The official website for TG Therapeutics is www.tgtherapeutics.com.

TG Therapeutics is headquartered at 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014.

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at (212) 554-4484 or via email at [email protected]